Interstitial Cystitis Drugs Market size is expected to cross USD 42 billion by the end of 2036, growing at a CAGR of 5% during the forecast period i.e., 2024 – 2036. In the year 2023, the industry size of interstitial cystitis drugs was USD 19 billion. The growth of this market can be attributed to the increasing product launches and drug approvals in the field of interstitial cystitis. The market players are highly intending on drug approvals and product launches by regulatory authorities that are expected to boost the market growth in the projected period. Such as in December 2019 the US Food and Drug Administration released a draft guidance detailing recommendations for the development of novel medications for the treatment of people with interstitial cystitis/bladder pain syndrome (IC/BPS).
Bladder pain and symptoms of the lower urinary tract are characteristics of interstitial cystitis. Although the precise etiology of the illness is unknown, many people, particularly women, are affected by it. Interstitial cystitis tends to be more common in women and is linked to a number of comorbid conditions, including endometriosis, fibromyalgia, and allergies. Current studies suggest that symptoms consistent with the diagnosis of interstitial cystitis occur in 2.7% to 6.5% of women in the United States.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~5% |
|
Base Year Market Size |
~USD 19 billion |
|
Forecast Year Market Size |
~USD 42 billion |
|
Regional Scope |
|
Growth Drivers
Challenges
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
In terms of distribution channel, the hospital pharmacies segment is set to hold the largest market share of 40% by the end of 2036. Hospitals are primary setting for the diagnosis and treatment of interstitial cystitis. Patients with interstitial cystitis demand for prescription medications, that are typically dispensed by hospital pharmacies. Besides, hospitals pharmacies are also experienced in managing interstitial cystitis medications. They can provide patients with counselling on how to take their medication and monitor side effects.
Type [Nonsteroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Antihistamines, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO), Hyaluronic Acid (Cystistat)]
Based on the product, dimethyl sulfoxide segment in the interstitial cystitis drugs market is set to hold the highest CAGR during the assessment period. The segment gains since it is the most recent interstitial cystitis treatment and is thought to lessen swelling and pain associated with the condition. It could increase blood flow to the area being treated. Additionally, the US Food and Drug Administration (FDA) authorized the use of dimethyl sulfoxide (DMSO) on November 4, 2021, to treat interstitial cystitis. As a result, the demand for the medicine has skyrocketed.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North America Market Forecasts
The interstitial cystitis drugs market in the North American is set to hold the highest growth of 33% during the anticipated period. The market is anticipated to grow as a result of a number of factors, including an increase in interstitial cystitis cases, increased research funding, improvements in interstitial cystitis diagnostic imaging, and widespread use of interstitial cystitis medications in the area. Some instances include interstitial cystitis (IC), which affected 5,894,905 people in the United States in 2018. In comparison, in the United States in 2020, the 8 million women.
APAC Market Statistics
The Asia Pacific interstitial cystitis drugs market is estimated to grow significantly during the projected timeframe. The growth of this market can be ascribed to the back of increasing population in the region. The population of the Asia Pacific region is growing rapidly, especially in India and China which further is leading to a high number of people getting affected by interstitial cystitis. Therefore, this is raising the demand for interstitial cystitis drugs in the Asia Pacific region. Besides, increasing urbanization activities in the APAC region are also considered to contribute to the market growth in this region. As escalating urbanization leads to advanced healthcare services and medication that also includes interstitial cystitis drugs.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?